Last reviewed · How we verify
MELITAC 12.1
At a glance
| Generic name | MELITAC 12.1 |
|---|---|
| Sponsor | University of Virginia |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Anemia
- constipation
- injection site reaction
- fatigue
- left eyelid stye
- cellulitis
- aspartate aminotransferase increased
- Creatinine increased
- hyperglycemia
- rash maculopapular
- hypertension
- Thrombocytopenia
Key clinical trials
- Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma (PHASE2)
- Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma (PHASE2)
- Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma (PHASE1)
- Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma (PHASE1)
- A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MELITAC 12.1 CI brief — competitive landscape report
- MELITAC 12.1 updates RSS · CI watch RSS
- University of Virginia portfolio CI